| DIRECT COMPETITOR COMPARISON | |
| USNA | Pvt1 | AVP | MTEX | Industry | | Market Cap: | 468.03M | N/A | 14.81B | 69.38M | 93.02M | | Employees: | 948 | N/A | 42,000 | 540 | 280 | | Qtrly Rev Growth (yoy): | 3.30% | N/A | -3.50% | -8.60% | 9.60% | | Revenue (ttm): | 431.21M | N/A | 10.01B | 296.12M | 71.35M | | Gross Margin (ttm): | 79.25% | N/A | 62.50% | 33.73% | 50.77% | | EBITDA (ttm): | 57.19M | N/A | 1.30B | -13.62M | 220.78K | | Oper Margins (ttm): | 11.61% | N/A | 11.26% | -8.80% | 7.24% | | Net Income (ttm): | 27.84M | N/A | 590.00M | -18.90M | N/A | | EPS (ttm): | 1.800 | N/A | 1.376 | -0.714 | N/A | | P/E (ttm): | 16.99 | N/A | 25.21 | N/A | 15.93 | | PEG (5 yr expected): | 0.94 | N/A | 1.87 | N/A | 0.97 | | P/S (ttm): | 1.12 | N/A | 1.51 | 0.25 | 1.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AVP | | '10 Feels Pretty, Oh So Pretty
Fri, Nov 27 -
Investor's Business Daily | | • | MTEX | | Mannatech's Educational Web Site Receives Web Health Merit Award
Tue, Nov 24 -
Business Wire | | • | AVP | | Amazon: Analysts' Upgrades, Downgrades
Mon, Nov 23 -
at TheStreet.com | | • | MTEX | | Investors Find Fat Gains in Nutrition Stocks
Tue, Nov 17 -
Indie Research | | • | AVP | | Why Consumers Still Spend on Beauty
Tue, Nov 17 -
at Minyanville.com | | • | AVP | | [video] Options Plays on Colgate-Palmolive Co.: Mad About Options
Tue, Nov 17 -
at TheStreet.com | | • | AVP | | Avon Products (AVP): Zacks Rank Buy
Mon, Nov 16 -
Zacks.com | | • | AVP | | [video] Value Investor Follows Buffett's Money [4.5 min]
Fri, Nov 13 -
at MarketWatch | | • | MTEX | | MANNATECH INC Financials
Tue, Nov 10 -
EDGAR Online Financials | | • | MTEX | | Mannatech Introduces PhytoBurst Nutritional Chews
Mon, Nov 9 -
Business Wire | | • | MTEX | | MANNATECH INC Files SEC form 10-Q, Quarterly Report
Thu, Nov 5 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
